PFIZER - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.8
| Stock Code | PFIZER | Market Cap | 21,362 Cr. | Current Price | 4,677 ₹ | High / Low | 5,993 ₹ |
| Stock P/E | 28.2 | Book Value | 919 ₹ | Dividend Yield | 0.75 % | ROCE | 24.2 % |
| ROE | 18.0 % | Face Value | 10.0 ₹ | DMA 50 | 4,787 ₹ | DMA 200 | 4,906 ₹ |
| Chg in FII Hold | 0.10 % | Chg in DII Hold | -0.16 % | PAT Qtr | 193 Cr. | PAT Prev Qtr | 182 Cr. |
| RSI | 45.2 | MACD | -22.4 | Volume | 21,543 | Avg Vol 1Wk | 31,379 |
| Low price | 4,460 ₹ | High price | 5,993 ₹ | PEG Ratio | 3.49 | Debt to equity | 0.02 |
| 52w Index | 14.2 % | Qtr Profit Var | -2.64 % | EPS | 158 ₹ | Industry PE | 30.5 |
📊 Chart Analysis: Pfizer is trading at ₹4,677, below both its 50 DMA (₹4,787) and 200 DMA (₹4,906), showing mild bearish pressure. RSI at 45.2 indicates neutral momentum leaning oversold. MACD at -22.4 confirms weak momentum with bearish crossover. Bollinger Bands suggest price near the lower band, with support around ₹4,460.
📈 Volume Trends: Current volume (21,543) is lower than the 1-week average (31,379), reflecting reduced participation and lack of strong buying interest.
🔑 Momentum Signals: Short-term momentum is weak, with consolidation signs. Support lies near ₹4,460, resistance around ₹4,900–₹5,000. Optimal entry zone: ₹4,500–₹4,600. Exit zone: ₹4,900–₹5,000 if momentum improves.
📉 Trend Status: The stock is consolidating with slight bearish bias. A reversal may occur if RSI moves above 50 and price sustains above 200 DMA.
Positive
- ✅ Strong ROCE (24.2%) and ROE (18%) show efficient capital use.
- ✅ Very low debt-to-equity ratio (0.02) ensures financial stability.
- ✅ Dividend yield (0.75%) adds investor confidence.
Limitation
- ⚠️ PEG ratio of 3.49 suggests overvaluation relative to growth.
- ⚠️ EPS growth is modest, with quarterly profit variation at -2.64%.
- ⚠️ Trading below both 50 DMA and 200 DMA signals weak momentum.
Company Negative News
- ❌ Decline in quarterly PAT (193 Cr vs 182 Cr) shows slowing profitability.
- ❌ Slight reduction in DII holdings (-0.16%) reflects cautious domestic sentiment.
Company Positive News
- 🌟 Increase in FII holdings (+0.10%) indicates foreign investor confidence.
- 🌟 Stable dividend payouts and strong balance sheet support long-term investors.
Industry
- 🏥 Pharma industry PE at 30.5 is slightly higher than Pfizer’s PE (28.2), suggesting fair valuation.
- 📊 Sector growth remains resilient with defensive demand, though competition is intense.
Conclusion
Pfizer is in a consolidation phase with weak short-term momentum. Entry near ₹4,500–₹4,600 offers favorable risk-reward, while exits around ₹4,900–₹5,000 are optimal unless strong breakout signals emerge. Long-term fundamentals remain solid, but near-term technicals suggest caution.